Transdermal drug delivery devices having coated microprotrusions
    2.
    发明授权
    Transdermal drug delivery devices having coated microprotrusions 有权
    透皮药物递送装置具有包被的微突起

    公开(公告)号:US08663155B2

    公开(公告)日:2014-03-04

    申请号:US11347779

    申请日:2006-02-02

    IPC分类号: A61M37/00

    摘要: A device (12) and method are provided for percutaneous transdermal delivery of a potent pharmacologically active agent. The agent is dissolved in water to form an aqueous coating solution having an appropriate viscosity for coating extremely tiny skin piercing elements (10). The coating solution is applied to the skin piercing elements (10) using known coating techniques and then dried. The device (12) is applied to the skin of a living animal (e.g., a human), causing the microprotrusions (10) to pierce the stratum corneum and deliver a therapeutically effect dose of the agent to the animal.

    摘要翻译: 提供了用于经皮透皮递送有效药理活性剂的装置(12)和方法。 将试剂溶解在水中以形成具有适当粘度的水性涂料溶液,以涂覆极微小的皮肤刺穿元件(10)。 使用已知的涂覆技术将涂布溶液施加到皮肤刺穿元件(10)上,然后干燥。 将装置(12)施加到活动物(例如人)的皮肤上,导致微突起(10)刺穿角质层并将治疗有效剂量的药剂递送至动物。

    Methods for imaging atherosclerotic plaque
    4.
    发明授权
    Methods for imaging atherosclerotic plaque 失效
    成像动脉粥样硬化斑块的方法

    公开(公告)号:US5026537A

    公开(公告)日:1991-06-25

    申请号:US334459

    申请日:1989-04-06

    摘要: This invention pertains to a method of imaging atherosclerotic plaque using radiolabeled monoclonal antibodies that are specific for activated platelets or activated endothelial cells. The method is capable of determining the site of endothelial injury. This method involves the administration of a platelet-specific labeled monoclonal antibody or antibody fragment to a patient. The antibody is allowed to accumulate at the plaque site and the plaque is then scanned with a photoscanner. The detected signals are then converted into an image of the plaque.

    摘要翻译: 本发明涉及使用对活化的血小板或活化的内皮细胞特异的放射性标记的单克隆抗体成像动脉粥样硬化斑块的方法。 该方法能够确定内皮损伤部位。 该方法涉及向患者施用血小板特异性标记的单克隆抗体或抗体片段。 允许抗体在斑块部位积聚,然后用照相扫描仪扫描斑块。 然后将检测到的信号转换成斑块的图像。

    Reduction of skin reactions caused by transdermal drug delivery
    9.
    发明授权
    Reduction of skin reactions caused by transdermal drug delivery 失效
    减少透皮给药引起的皮肤反应

    公开(公告)号:US06203817B1

    公开(公告)日:2001-03-20

    申请号:US09092606

    申请日:1998-06-05

    IPC分类号: A61F1302

    CPC分类号: A61K9/7053 A61K9/7084

    摘要: Transdermal compositions, devices, and methods for the administration of a drug at reduced skin irritation levels are disclosed. More particularly, this invention relates to novel methods, compositions, and devices for the reduction or elimination of irritation or sensitization caused by an irritating or sensitizing drug when it is delivered transdermally. According to a preferred embodiment, transdermal administration of a drug salt of a non-zwitterionic drug is disclosed wherein the drug salt comprises a combination of surface activity and a low octanol-water partition coefficient. Such drug salts have been found to reduce irritation or sensitization to the drug being delivered while achieving therapeutically effective transdermal fluxes.

    摘要翻译: 公开了用于在皮肤刺激水平降低的药物给药的透皮组合物,装置和方法。 更具体地说,本发明涉及当通过皮肤递送时由刺激性或致敏性药物引起的刺激或致敏的减少或消除的新方法,组合物和装置。 根据优选的实施方案,公开了非两性离子药物的药物盐的透皮给药,其中所述药物盐包含表面活性和低辛醇 - 水分配系数的组合。 已经发现,这些药物盐可以减少对所递送药物的刺激或致敏,同时实现治疗有效的经皮通气。